Effective and Accurate CNV Calling Using the PiVAT Bioinformatics Platform

Pillar Biosciences

In this study, researchers used the Pillar variant analysis toolkit (PiVAT), Pillar’s bioinformatics software to detect CNVs.

Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients

Xian Hua Gao, Guan Yu Yu, Yong Gang Hong, Wei Lian, Hanumant Chouhan, Yi Xu, Lian Jie Liu, Chen Guang Bai, Wei Zhang

IJCO, January 2019; 10.1007/s10147-018-1377-1

For this publication, researchers used the ONCO/Reveal Lung and Colon Cancer Panel to detect multiple mutations in FFPE specimens from colorectal cancer patients

Heterogenous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing

Qiaomei Guo, Junlei Wang, Jianfeng Xiao, Lin Wang, Xiaomeng Hu, Wenjun Yu, Gang Song, Jiatao Lou, JianFeng Chen

Molecular Cancer, August 2018; 10.1186/s12943-018-0875-0

In this study, researchers used Pillar Biosciences technology to examine concordance between mutations detected in FFPE samples and cfDNA samples from the same patients.

Amplification of overlapping DNA amplicons in a single-tube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2

Desiree Schenk, Gang Song, Yue Ke, Zhaohui Wang

PLOSone, July 2017; 12(7): e0181062.

This paper outlines Pillar Biosciences’ method and further development of the SLIMamp™ technology, and also describes the results of full-gene BRCA1 and BRCA2 panel as applied to cell line DNA and remnant human DNA samples.

Feasibility study of molecular profiling of gastric cancer specimens from Rwanda

Mary D. Chamberlin, Belson Rugwizangoga, Francine B. DeAbreu, Eric Rutaganda, Vincent Dusabejambo, Oswald Habyarimana, Steve Bensen, Gregory J. Tsongalis

JGO, April 2017; 10.1200/JGO.2017.009605

This publication describes meeting proceedings in which researchers from Dartmouth-Hitchcock Medical Center and the University of Rwanda College of Medicine and Health Sciences describe how they used reagents provided by Pillar Biosciences to create and test a research platform for testing FFPE gastric cancer samples collected in Rwanda in the United States.